Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease

Author:

Yen Fu-Shun,Hsu Chih-Cheng,Wei James Cheng-Chung,Hou Ming-Chih,Hwu Chii-Min

Abstract

The global prevalence of chronic liver disease and diabetes mellitus (DM) has gradually increased potentially due to changes in diet and lifestyle. The choice of antidiabetic medications for patients with coexisting DM and chronic liver disease is complicated. Severe liver injury may decrease the metabolism of antidiabetic medications, resulting in elevated drug concentrations and adverse effects. The choice of antidiabetic medications in patients with chronic liver disease has not been well studied. The long-term outcomes of antidiabetic medications in patients with chronic liver disease have gained attention recently. Herein, we reviewed relevant articles to extend our understanding on the selection and warning of antidiabetic medications for patients with chronic liver disease.

Publisher

Frontiers Media SA

Subject

General Medicine

Reference93 articles.

1. Data Resources, GBD Results Tool, Terms and Conditions.2019

2. IDF Diabetes Atlas,2019

3. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management;Garcia-Compean;World J Gastroenterol.,2009

4. Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment;Gangopadhyay;Ind J Endocrinol Metab.,2017

5. Diabetes mellitus in patients with cirrhosis: clinical implications and management;Elkrief;Liver Int.,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3